Cholesterol crystal embolism (CCE) is a serious complication associated with invasive vascular procedures. The prognosis of the renal involvement type of CCE is very poor, and there is currently no established treatment, other than supportive therapy. We herein report four cases of CCE with severe atherosclerosis wherein the renal function progressively deteriorated after cardiac catheterization. In three of the four patients, lowdose corticosteroids (0.3 mg/kg/day) improved the renal function, whereas the fourth patient died from CCE of the digestive system. This report reviews the literature on CCE and discusses possible therapeutic options.
Introduction
Cholesterol crystal embolism (CCE) is a systemic disorder caused by the occlusion of small-to medium-sized arteries by atheromatous material derived from ulcerated atherosclerotic plaques in the aorta or large feeder arteries. Although CCE may occur spontaneously, it often occurs as a complication of mechanical manipulation of the aorta during angiography or cardiac or vascular surgery. Because CCE can spread to almost any organ, its clinical presentation is diverse, ranging from relatively benign involvement in the lower limbs to life-threatening, multiple organ dysfunction, including renal failure, heart failure, gastrointestinal ischemia, pancreatitis, muscle ischemia and skin necrosis. The development of multiple organ ischemia leads to serious morbidity and mortality in 64-81% of patients (1, 2) . However, despite such dire outcomes, there is no definitive treatment for CCE.
Recently, several reports have suggested that corticosteroid therapy might be effective in treating CCE. We herein report four cases of histologically proven CCE treated with corticosteroids. Three of the four patients were treated successfully with a low dosage of corticosteroids, and one patient died of gastrointestinal complications.
Case Reports

Case 1
A 59-year-old man was admitted to our hospital due to a progressive deterioration of his renal function and a recent onset of leg pain with blue toes. Three weeks before admission, he underwent coronary angiography (CAG) and aortography via the brachial approach to evaluate symptomatic angina pectoris and peripheral arterial disease (PAD). His initial creatinine level was 2.82 mg/dL; however, it increased over the next four weeks to 4.61 mg/dL. On admission, a physical examination revealed cyanosis of the toes with normal pedal arterial pulses and livedo reticularis in both legs (Table 1) . Laboratory investigations showed a marked peripheral blood eosinophilia of 13% with a normal white blood cell count (WBC) of 8,050/μL ( Table 2 ). The progressive renal dysfunction with marked eosinophilia and livedo reticularis was thought to result from CCE, and skin and renal biopsies were performed. The renal biopsy demonstrated a needle-shaped cleft in the arterial lumen consistent with CCE (Fig. 1A ). Crystals were also found on a skin biopsy of the acrocyanotic toes. Starting on the fifth hospital day, low-density lipoprotein apheresis (LDL-A) with dextran sulfate cellulose columns (Liposorber LA-15, Kaneka Corporation, Osaka) was performed once a week for over three months (10 treatments in total). Minor improvement of the leg pain and livedo reticularis was noted after a few sessions of LDL-A treatment; however, there was no improvement in either the renal function or the acrocyanotic toes. Therefore, following the fourth LDL-A session (the 28th hospital day), oral prednisolone was administered at a dose of 20 mg/day, which promptly ameliorated the eosinophilia within a few days and gradually decreased the creatinine level to 3.15 mg/dL within four weeks. In addition, both the cyanosis of the toes and the leg pain resolved. Although the dose of steroids was slowly tapered and eventually stopped 12 months later, the patient's renal function has been maintained and there has been no further occurrences of renal failure for the past two years.
(Clinical findings and laboratory data for all cases are shown in Table 1 and Table 2 .)
Case 2
A 70-year-old man was admitted to our hospital due to a progressive deterioration of his renal function and acute heart failure with severe pulmonary congestion. The patient had a 20-year history of untreated hypertension and dyslipidemia and he was also a heavy smoker. Seven months before the current admission, he was admitted to the hospital due to an initial episode of congestive heart failure. Echocardiography revealed diffuse left ventricular (LV) hypertrophy (interventricular septal thickness: 14 mm, posterior wall thickness: 14 mm) and diffuse mild impairment of LV contractions (a LV ejection fraction of 45%) without LV dilatation. After the cardiac function was improved with medical treatment, the patient underwent CAG via the brachial approach to rule out ischemic heart disease. CAG showed moderate stenosis in the distal portion of the right coronary artery. Before CAG, the initial creatinine level was 1.99 mg/ dL, which increased gradually over the next six months to 6.02 mg/dL. Seven months after CAG, the patient was read- (Table 1) . Laboratory blood investigations showed progressive renal dysfunction (blood urea nitrogen (BUN): 83 mg/dL, creatinine: 7.12 mg/dL), leukocytosis with marked eosinophilia (WBC: 16,840/μL, eosinophils: 5,136/μL) and a C-reactive protein (CRP) level of 5.6 mg/ dL (Table 2 ). Due to the patient's respiratory dysfunction caused by pulmonary congestion and advanced renal failure, hemodialysis therapy was instituted on the first hospital day. On the fifth hospital day, a skin biopsy obtained from the area of acrocyanosis of the toes showed nonspecific inflammatory cell infiltration around a deep dermal artery; however, no crystal clefts were seen. Therefore, a renal biopsy was performed on the 10th hospital day, and the specimen showed needle-shaped cholesterol clefts within small arteries and glomerular capillaries (Fig. 1B) , consistent with a diagnosis of CCE. To treat the CCE, oral prednisolone was administered at a dose of 20 mg/day starting on the 15th hospital day, resulting in amelioration of the eosinophilia and livedo reticularis within a few days. The patient's serum creatinine level gradually decreased one week after the initiation of prednisolone. Hemodialysis was stopped on the 45th hospital day due to improvement of the renal function (BUN: 64 mg/dL, creatinine: 3.83 mg/dL), and the patient was discharged on the 62nd hospital day. To date, two years after the cessation of hemodialysis, the patient's renal function has stabilized with a serum creatinine level of 3.5 mg/ dL.
Case 3
A 71-year-old man was admitted to our hospital due to progressive deterioration of the renal function and recent onset of leg pain with livedo reticularis. Six weeks before this admission, the patient had undergone CAG and aortography for an evaluation of symptomatic angina pectoris and PAD. Severe stenosis of the LAD and thrombotic occlusion with severe stenosis of the left external iliac artery (EIA) were discovered. The patient subsequently underwent successful percutaneous coronary intervention (PCI) via the right femoral artery and was treated with warfarin for occlusion of the left EIA. The initial creatinine level was 1.62 mg/dL; however, it increased over the next six weeks to 2.38 mg/dL. During the latest admission, a physical examination revealed acrocyanosis of the toes and livedo reticularis in both legs (Table 1) . Laboratory blood investigations showed progression of renal dysfunction (BUN: 39 mg/dL, creatinine: 2.38 mg/dL), marked eosinophilia (WBC: 8,560/μL, eosinophils: 1,880/μL) and a CRP level of 0.58 mg/dL (Table 2) . On the first hospital day, a skin biopsy was performed on the affected area of the left thigh and the sole of the left foot, 
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which demonstrated characteristic cholesterol clefts in the small arteries (Fig. 1C) . On the fifth hospital day, anticoagulant therapy was discontinued and oral prednisolone was administered at a dose of 20 mg/day. On the 10th hospital day, LDL-A using the same system detailed in Case 1 was performed once a week for over three months (10 treatments in total). The eosinophilia was ameliorated within two weeks of the administration of oral prednisolone and LDL-A treatment, and the creatinine level gradually decreased from 2.81 to 2.37 mg/dL over the next two months. The acrocyanosis of the toes, leg pain and livedo reticularis immediately resolved. The dose of prednisolone was slowly tapered, and the drug is currently being administered at a dose of 5 mg/ day. One year after the admission, the patient remains asymptomatic with a creatinine level of 2.11 mg/dL and a BUN level of 28 mg/dL.
Case 4
A 68-year-old man with a 20-year history of hypertension and dyslipidemia who was known to have an abdominal aortic aneurysm (AAA) was referred for an evaluation of progressive deterioration of the renal function, epigastralgia, anorexia and general malaise.
Six weeks prior to his current admission, he underwent CAG and aortography via the radial approach for a preoperative evaluation of AAA at another hospital. At that time, the creatinine level was 1.56 mg/dL.
One week after the procedure, he complained of recurrent epigastric pain, general malaise and appetite loss. The creatinine level increased over the next four weeks to 2.57 mg/ dL. On admission, a physical examination revealed hypertension (a blood pressure of 156/91 mmHg), acrocyanosis of the toes and livedo reticularis in both legs (Table 1) . Laboratory blood investigations showed progressive renal dysfunction (BUN: 22 mg/dL, creatinine: 3.79 mg/dL), leukocytosis with eosinophilia (WBC: 9,150/μL, eosinophils: 805/μL) and a CRP level of 0.3 mg/dL (Table 2) . A skin biopsy and a renal biopsy were performed on the first and fifth hospital days, respectively, both of which showed nonspecific perivasculitis without cholesterol clefts.
Although there was no histopathological proof, CCE was nevertheless diagnosed due to the recent angiography findings, the clinical presentation of progressive renal dysfunction, the typical skin symptoms manifested in the lower extremities and the presence of eosinophilia. Consequently, oral prednisolone was administered at a dose of 20 mg/day starting on the fifth hospital day. Following the administration of prednisolone, the eosinophilia and livedo reticularis resolved within one week, and the creatinine level gradually decreased to 3.3 mg/dL over the next three weeks. Due to intermittent abdominal pain associated with nausea during hospitalization, the patient underwent computed tomography (CT) one month after admission, which revealed an infrarenal AAA with a diameter of 4.5 cm and severe atheromatous plaque with ulcerations in the aorta (Fig. 2) . He also underwent upper gastrointestinal endoscopy and colonoscopy during the same period, which showed nonspecific abnormalities except for a superficial erosion of the antrum mucosa. However, one and a half months after hospitalization, discoloration of the great right toe reappeared along with a relapse of the renal function and recurrence of eosinophilia.
On the 88th hospital day, the patient complained of severe persistent abdominal pain. A physical examination showed abdominal distension and diffuse tenderness with muscle guarding on gentle palpation. An emergency CT scan revealed a small amount of ascites and intraperitoneal free air, which suggested a perforation of the digestive system. Emergency surgery was performed, which revealed gangrenous changes in nearly the entire small intestine as well as the ascending colon and a perforation in the jejunum measuring 3 mm in diameter. Subsequently, resection of the diseased bowel (a large part of the small intestine and right hemicolon) was performed. A histopathological examination of the resected small intestine revealed ischemic necrosis and numerous cholesterol clefts within the small submucosal arteries, consistent with a diagnosis of ischemic bowel necrosis with perforation caused by CCE (Fig. 1D) . Following the operation, the patient's renal function continued to deteriorate, requiring hemodialysis. In fact, his general condition rapidly deteriorated, culminating in multiorgan failure that lead to his death one month after surgery. Permission to perform an autopsy was denied.
Discussion
Initially reported by Flory in 1945, CCE is a systemic disease caused by occlusion of the small arteries by cholesterol crystals measuring 150-200 μm in diameter derived from ulcerated atherosclerotic plaques (3) . Because the abdominal aorta is the most common source of cholesterol crystals, the kidneys, intestines and lower extremities are at prime risk of embolization (4) . Skin lesions are the most common manifestations, appearing in 69% to 96% of patients (2, (5) (6) (7) (8) . Deterioration of the renal function is also one of the most common manifestations of CCE. Its course is usually subacute, occurring gradually over four to six weeks; however, acute renal failure with necrotizing glomerulonephritis has also been reported. Generally, the renal prognosis is poor, and dialysis is required in 40-61% of patients with acute or subacute renal CCE. Furthermore, only 14-21% of patients recover a sufficient renal function to discontinue dialysis (1, 5, 9) .
Although the disease can occur spontaneously, it usually develops after invasive vascular procedures such as manipulation of the aorta during angiography or vascular surgery and can also occur following the use of anticoagulants or thrombolytic agents (6, 9) . CCE has been estimated to occur after vascular procedures in 0.15% to 1.4% of cases in clinical studies (10, 11) . In the present cases, at least one invasive vascular procedure was performed prior to the onset of CCE in each patient, including CAG in all four patients, aortography in two patients and warfarin use in one patient. Therefore, contrast nephropathy should be considered in the differential diagnosis of renal dysfunction. In contrast nephropathy, renal dysfunction usually occurs within 48 to 72 hours after infusion followed by a slow recovery to the baseline level within two weeks. In all of the present cases, progressive renal dysfunction developed several weeks after the vascular procedures and persisted for more than four weeks; therefore, the renal dysfunction in each case is thought to be primarily related to renal CCE.
When the clinical manifestation of CCE is limited to the skin of the lower extremities, the clinical course seems to be relatively benign. However, for multiple visceral types of CCE, the prognosis is very poor, and the mortality rate at one year is between 64-81% (2, 8) . Although the mortality rate is very high and the frequency of this disease is expected to increase, there is currently no established treatment other than supportive therapy, which includes discontinuing anticoagulation, avoiding further invasive vascular procedures and controlling hypertension and dialysis. Several drugs and therapeutic options have been used to treat CCE, including corticosteroids, statins and LDL-A. Recently, corticosteroid therapy has been reported to be beneficial for CCE patients in reducing local and general inflammatory responses (12) (13) (14) (15) . Nakayama et al. reported that low-dose corticosteroids (10-20 mg/day (0.3 mg/kg/day)) achieved favorable, short-term renal outcomes in CCE patients (16) .
According to the theory proposed by Jones and Iannaccone, CCE-induced vascular changes occur in three phases: (I) an early phase consisting of fresh crystal emboli causing endothelial injury and early histiocytic responses, (II) an intermediate phase characterized by giant cell reactions and intimal proliferation and (III) a late phase in which the crystals are entrapped by histiocytes and additional intimal proliferation and fibrous tissue formation occur (17) . Based on this theory, steroids may attenuate the CCE-induced clinical picture by inhibiting the inflammatory response in the first two phases of the disease. Cheng et al. described how corticosteroid treatment for CCE upregulates the activation of the phagocytic capacity of Kupffer cells, mediated by the overexpression of receptors for advanced glycation end-products and scavenger receptors. In turn, this might result in the efficient clearance from blood circulation of the lipid substances released by atherosclerotic areas (18) .
Various methods of administering corticosteroids have been reported; however, no ideal dosages or durations of therapy have been established. Several reports have shown favorable effects of high-dose corticosteroid therapy on CCE-induced renal deterioration (19, 20) , although the use of high-dose corticosteroids increases the risk of cardiovascular side effects and opportunistic infections, especially in elderly and diabetic patients. Nakayama et al. reported that low-dose corticosteroids (10-20 mg/day (0.3 mg/kg/day)) achieved favorable, short-term renal outcomes in CCE patients (16) . In our cases, we initiated steroid therapy at a dose of 20 mg/day following CCE diagnosis.
In previous reports, tapering or withdrawal of corticosteroids resulted in the progression of disease, and increasing the dose or resuming the drug was required (19, 21, 22) . Therefore, we slowly tapered the corticosteroids at a rate of 5 mg at an interval of approximately four weeks following confirmation of the absence of a worsening renal function and re-elevation of eosinophils. Finally, corticosteroids were tapered to a maintenance dose of 2.5-5 mg/day and eventually discontinued only if the symptoms and renal function remained stable over the next six months.
In the present cases, administering corticosteroids resulted in rapid amelioration of symptoms and eosinophilia and gradual recovery of the renal function. Although previous reports have suggested that steroid therapy lacks efficacy in long-term renal outcomes, in three of our cases, positive renal outcomes following CCE persisted not only in the shortterm, but also over the long-term (16) . In fact, in Case 2, dialysis was no longer necessary only one month after corticosteroid administration due to sufficient recovery of the renal function, a recovery that continued long-term. In Case 1 and Case 3, LDL-A was administered in combination with corticosteroid treatment. In Case 1, small improvement of leg pain and livedo reticularis was observed after a few sessions of LDL-A; however, the renal function did not recover with LDL-A alone. In Case 3, we speculate that combination therapy with low-dose corticosteroids and LDL-A was effective as treatment for CCE. Several previous reports have shown that LDL-A improves cutaneous manifestations of CCE but not the renal function without combination with corticosteroids (14, 23, 24) . Tsunoda et al. reported that LDL-A might be more beneficial for CCE-induced damage to the skin and brain than the kidneys.
In Case 4, however, in spite of symptom amelioration and positive laboratory findings following the administration of corticosteroids, we were unable to save the patient from necrosis and perforation of the small intestine due to recurrent CCE. The patient complained of recurrent abdominal pain at the initial hospitalization, and re-exacerbation of eosinophilia, cutaneous findings and the renal function was observed in spite of the continuous administration of corticosteroids. These phenomena might have been due to the recurrent or continuous shedding and delivery of cholesterol crystals from severe ulcerated atheromatous plaques in the abdominal aneurysm, which resulted in the development of newly disseminated CCE. In such cases of massive and recurrent showering of CCE from a rich embolic source, lowdose corticosteroid treatment seems to have limited effects. Another therapeutic option might need to be considered such as high-dose corticosteroid treatment or combination therapy with LDL-A or statins.
In this case report, low-dose corticosteroids were used in four patients who presented with multiple visceral types of CCE after undergoing angiography or PCI, resulting in the dramatic and complete resolution of cutaneous manifestations and amelioration of the renal function in three of the four cases. Therefore, low-dose corticosteroid therapy seems to be a more reasonable and effective therapeutic approach than conventional supportive therapy alone. However, this is only a case report of a small number of patients. Large prospective and randomized controlled studies are necessary to confirm the efficacy of corticosteroid therapy for the clinical and renal outcomes in patients with CCE.
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